Magle Chemoswed Holding
27.4
SEK
-5.52 %
Less than 1K followers
MAGLE
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Ownership
Investor consensus
-5.52%
-8.67%
-15.43%
-21.26%
-26.84%
-8.31%
+4.19%
-
+36.36%
The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed, a contract development and manufacturing organization (CDMO). Magle PharmaCept, an established sales and marketing company for the development and direct sales of the Groups medical technology products, and Magle Biopolymers A/S, a specialized manufacturing organization of Dextran technology.
Read moreMarket cap
562.14M SEK
Turnover
65.69K SEK
Revenue
236.04M
EBIT %
9.84 %
P/E
0.62
Dividend yield-%
-
Financial calendar
9/5
2025
Interim report Q1'25
26/5
2025
General meeting '25
1/8
2025
Interim report Q2'25
All
Press releases
3rd party
ShowingAll content types
Correction: Magle Chemoswed Holding Reports Financial Results For Fourth Quarter 2024
Magle PharmaCept Partners with Pancreatic Cancer Europe PCE to Advance Innovation in Pancreatic Cancer Care
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools